(Q37482527)

English

Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma

scientific article published on January 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma (English)

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

0 references

0 references

Andrew D Zelenetz

9

object named as

A D Zelenetz

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

author name string

R Schaffel

1

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

C V Hedvat

2

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

J Teruya-Feldstein

3

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

D Persky

4

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

J Maragulia

5

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

D Lin

6

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

C S Portlock

7

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

C H Moskowitz

8

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

publication date

1 January 2010

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Annals of Oncology

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

21

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

1

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

133-139

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795614

23 August 2017

Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795614

23 August 2017

RETRACTED: Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795614

23 August 2017

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795614

23 August 2017

Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795614

23 August 2017

Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795614

23 August 2017

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795614

23 August 2017

Minichromosome maintenance protein 6, a proliferation marker superior to Ki-67 and independent predictor of survival in patients with mantle cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795614

23 August 2017

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795614

23 August 2017

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795614

23 August 2017

Outcome of deferred initial therapy in mantle-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795614

2 September 2018

Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cyta

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795614

2 September 2018

Mantle Cell International Prognostic Index (MIPI) not prognostic after R-hyper-CVAD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795614

2 September 2018

Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795614

2 September 2018

Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: res

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795614

2 September 2018

Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795614

2 September 2018

A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795614

2 September 2018

Mantle-cell lymphoma: a population-based clinical study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795614

2 September 2018

Patterns of survival in mantle cell lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795614

2 September 2018

High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen

1 reference

https://pubmed.ncbi.nlm.nih.gov/20019090

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20019090

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunohistochemical detection of cdc2 is useful in predicting survival in patients with mantle cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20019090

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20019090

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/ANNONC/MDP495

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37482527&oldid=2172513776"